Lost in translation: neuropsychiatric drug development.
- Authors
- Becker, Robert E; Greig, Nigel H
- Year
- 2010
- Journal
- Science translational medicine
- PMID
- 21148128
- DOI
- 10.1126/scitranslmed.3000446
- PMCID
- PMC5178822
Recent studies have identified troubling method and practice lapses in neuropsychiatric drug developments. These problems have resulted in errors that are of sufficient magnitude to invalidate clinical trial data and interpretations. We identify two potential sources for these difficulties: investigators selectively choosing scientific practices for demonstrations of efficacy in human-testing phases of drug development and investigators failing to anticipate the needs of practitioners who must optimize treatment for the individual patient. When clinical investigators neglect to use clinical trials as opportunities to test hypotheses of disease mechanisms in humans, the neuropsychiatric knowledge base loses both credibility and scope. When clinical investigators do not anticipate the need to translate discoveries into applications, the practitioner cannot provide optimal care for the patient. We conclude from this evidence that clinical trials, and other aspects of neuropsychiatric drug development, must adopt more practices from basic science and show greater responsiveness to conditions of clinical practice. We feel that these changes are necessary to overcome current threats to the validity and utility of studies of neurological and psychiatric drugs.
Problems in neuropsychiatric drug discovery.
Inadequate options for neuropsychiatric patients.
The way forward.
The black hole of neuropsychiatry drug development.
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | 2018 | 29897633 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Uncovering NMDA receptor-mediated high firing activity in excitatory human neurons. | Gameiro-Ros I et al. | — | 2026 | → |
| What Remains to Be Discovered in Schizophrenia Therapeutics: Contributions by Advancing the Molecular Mechanisms of Drugs for Psychosis and Schizophrenia. | Correll CU et al. | — | 2024 | → |
| The foundation and architecture of precision medicine in neurology and psychiatry. | Hampel H et al. | — | 2023 | → |
| Drug repurposing: a systematic review on root causes, barriers and facilitators. | Krishnamurthy N et al. | — | 2022 | → |
| Targeting NMDA receptors in neuropsychiatric disorders by drug screening on human neurons derived from pluripotent stem cells. | Zhang W et al. | — | 2022 | → |
| Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study. | Loiodice S et al. | — | 2021 | → |
| Repurposing Immunomodulatory Imide Drugs (IMiDs) in Neuropsychiatric and Neurodegenerative Disorders. | Jung YJ et al. | — | 2021 | → |
| Why promising drugs are shelved and barriers and facilitators to re-purposing them: A systematic literature review | Krishnamurthy N et al. | — | 2021 | — |
| The Evolution of Stem Cells, Disease Modeling, and Drug Discovery for Neurological Disorders. | Pernia C et al. | — | 2020 | → |
| Towards High-Throughput Chemobehavioural Phenomics in Neuropsychiatric Drug Discovery. | Henry J et al. | — | 2019 | → |
| Does traumatic brain injury hold the key to the Alzheimer's disease puzzle? | Becker RE et al. | — | 2018 | → |
| Genetics of Alcohol Use Disorder: A Role for Induced Pluripotent Stem Cells? | Prytkova I et al. | — | 2018 | → |
| (-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. | Becker RE et al. | — | 2018 | → |
| Drug discovery and development: Role of basic biological research. | Mohs RC et al. | — | 2017 | → |
| Glial cells as drug targets: What does it take? | Möller T et al. | — | 2016 | → |
| Induced Pluripotent Stem Cells as a Novel Tool in Psychiatric Research. | Kim S et al. | — | 2016 | → |
| Mild traumatic brain injury-induced hippocampal gene expressions: The identification of target cellular processes for drug development. | Tweedie D et al. | — | 2016 | → |
| Policies and Consequences: How America and Psychiatry Took the Detour to Erewhon. | Becker RE | — | 2015 | → |
| The pain of pain: challenges of animal behavior models. | Barrett JE | — | 2015 | → |
| What can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general? | Becker RE et al. | — | 2015 | → |
| Advances in understanding Alzheimer's disease, and the contributions of current Alzheimer research: ten years on and beyond. | Greig NH et al. | — | 2014 | → |
| A new regulatory road-map for Alzheimer's disease drug development. | Becker RE et al. | — | 2014 | → |
| A new roadmap for drug development for Alzheimer's disease. | Becker RE et al. | — | 2014 | → |
| Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury. | Greig NH et al. | — | 2014 | → |
| Intrathecal delivery of protein therapeutics to the brain: a critical reassessment. | Calias P et al. | — | 2014 | → |
| Linking Alzheimer's disease and type 2 diabetes mellitus via aberrant insulin signaling and inflammation. | Kamal MA et al. | — | 2014 | → |
| Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. | Ashraf GM et al. | — | 2014 | → |
| Fire in the ashes: can failed Alzheimer's disease drugs succeed with second chances? | Becker RE et al. | — | 2013 | → |
| Implications and limitations of cellular reprogramming for psychiatric drug development. | Tobe BT et al. | — | 2013 | → |
| Neurotrophic and neuroprotective actions of (-)- and (+)-phenserine, candidate drugs for Alzheimer's disease. | Lilja AM et al. | — | 2013 | → |
| Increasing the success rate for Alzheimer's disease drug discovery and development. | Becker RE et al. | — | 2012 | → |
| Medication discovery for addiction: translating the dopamine D3 receptor hypothesis. | Newman AH et al. | — | 2012 | → |
| R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. | Loland CJ et al. | — | 2012 | → |
| Critical thoughts on current rodent models for evaluating potential treatments of alcohol addiction and withdrawal. | Ripley TL et al. | — | 2011 | → |
| Disclosure of clinical trial results when product development is abandoned. | Rogawski MA et al. | — | 2011 | → |
| Functional activity of the novel Alzheimer's amyloid β-peptide interacting domain (AβID) in the APP and BACE1 promoter sequences and implications in activating apoptotic genes and in amyloidogenesis. | Bailey JA et al. | — | 2011 | → |
| Scientific process, pharmacology and drug discovery. | Trist DG | — | 2011 | → |
| The secrets of a successful clinical trial: compliance, compliance, and compliance. | Czobor P et al. | — | 2011 | → |
| Why so few drugs for Alzheimer's disease? Are methods failing drugs? | Becker RE et al. | — | 2010 | → |